Impact of hyperuricemia on 5-year clinical outcomes following percutaneous transluminal angioplasty

초록

BACKGROUND: Although the correlation between hyperuricemia and cardiovascular disease (CVD) is well known, there have been limited data regarding the impact of hyperuricemia on long-term clinical outcomes in patients with peripheral arterial disease (PAD) after percutaneous transluminal angioplasty (PTA). METHODS: A total of 718 patients who underwent PTA for PAD were enrolled. The patients were divided into the hyperuricemia group (N&#xa0;=&#xa0;168) and the normal group (N&#xa0;=&#xa0;550). Hyperuricemia was defined as a uric acid level&#xa0;&#x2265;&#xa0;7.0&#xa0;mg/dL in men, and&#xa0;&#x2265;&#xa0;6.5&#xa0;mg/dL in women. The primary endpoint was major adverse cerebral and cardiovascular event (MACCE), including death, myocardial infarction (MI), any coronary revascularization, and stroke, up to 5&#xa0;years. The secondary endpoint was major adverse limb event (MALE), including any repeated PTA, and target extremity surgery (TES). Inverse probability weighting (IPTW) analysis, derived from the logistic regression model, was performed to adjust potential confounders. RESULTS: After IPTW matching analysis, compared to the normal group, the hyperuricemia group was not associated with increased MACCE but was associated with an increased incidence of MI (2.6&#xa0;% vs. 0.5&#xa0;%, p&#xa0;=&#xa0;0.001), and coronary revascularization (6.7&#xa0;% vs. 3.9&#xa0;%, p&#xa0;=&#xa0;0.018). Also, the hyperuricemia group was associated with a higher incidence of MALE (45.3&#xa0;% vs. 28.9&#xa0;%, p&#xa0;<&#xa0;0.001), including target extremity revascularization (TER; 25.1&#xa0;% vs. 15.9&#xa0;%, p&#xa0;<&#xa0;0.001), non-TER (11.5&#xa0;% vs. 5.6&#xa0;%, p&#xa0;<&#xa0;0.001), and TES (22.8&#xa0;% vs. 16.2&#xa0;%, p&#xa0;=&#xa0;0.002). CONCLUSIONS: In the present study, hyperuricemia was associated with worse clinical outcomes in PAD patients following PTA during 5-year clinical follow-up. Further investigations should be made regarding the clinical benefit of controlling hyperuricemia on clinical outcomes. Copyright © 2024 Elsevier Inc. All rights reserved.

키워드